ID | 1227 |
Name of the vaccine | GBS Trivalent vaccine |
Microbe | Bacteria |
Disease name | Streptococcal Disease, Group B |
Name of bacteria | Streptococcus agalactiae (Group B Streptococcus) |
Type of vaccine | Conjugate |
Nucleic acid content | Circular DNA |
Age | 18 to 40 years (pregnant women) |
Description of the vaccine | Trivalent Group B Streptococcus vaccine. |
Name of the manufacturer | Novartis |
Name of the manufacturing country | Belgium, Canada |
Year of manufacture | 2013 |
Clinical Phase status | Clinical - Phase 2 |
Bacterial strain | Gram-positive coccus. |
Efficacy | NA |
Vaccine formulation | NA |
Dosage | Single dose |
Mechanism of action | Induced antibodies which were transferred to the new born. |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT01446289 |
Reference | https://adisinsight.springer.com/drugs/800026395 |
Other name | NA |
Additional Links | NA
|